Randomized controlled trial finds urea-based cream reduces hand-foot skin reactions in advanced liver cancer patients on sorafenib, suggesting valuable prophylactic supportive care.
UBC prophylaxis in patients with advanced HCC starting sorafenib reduced HFSR rates, extended the time to first occurrence of HFSR, and improved patient quality of life compared with BSC. Blinded, randomized, placebo-controlled trials to determine the role of UBC on the incidence and severity of HFSR are warranted.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: